Fri.Jan 05, 2024

article thumbnail

Study finds no link between Novo Nordisk’s GLP-1 drugs and suicidal ideation

Fierce Pharma

Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medi | Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medical records of patients shows no link between use of the GLP-1 drugs and an increase in suicidal though

article thumbnail

19 Senators Urge HHS to Drop Appeal That Would Jeopardize Americans’ Access to Life-Saving Drugs

MedCity News

A bipartisan group of senators sent a letter to HHS asking it to rethink its appeal of a recent federal district court decision that limits the use of “copay accumulators” — which are programs insurers use to prevent medication copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.

Insurance 125
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Beleaguered Theravance logs head-to-head trial loss for Yupelri against Boehringer's Spiriva

Fierce Pharma

When Theravance called it quits on a phase 2 JAK inhibitor program last February, the South San Francisco and Dublin-based biopharma company put the majority of its chips on a head-to-head trial pi | In the phase 4 study, Theravance and Viatris’ Yupelri failed to demonstrate greater lung function improvement in adults with COPD versus Spiriva delivered by a dry powder inhaler, Theravance said Friday.

Biopharma 211
article thumbnail

Collaboration to develop novel AI-designed oncology therapy

European Pharmaceutical Review

Under a new licensing agreement, Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, gains the global rights to develop and commercialise a novel, small molecule KAT6A inhibitor. This treatment has potential for hormone sensitive cancers such as breast cancer, and other oncology indications. The therapeutic is designed using the artificial intelligence (AI)-platform from Insilico Medicine, the biotech company that is also part of this collaboration.

Medicine 115
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Fierce Pharma Asia—Deal spree by AstraZeneca, J&J, Roche, Boehringer and more; Big Pharma’s China strategy

Fierce Pharma

The last few days of 2023 and the beginning of 2024 featured a flurry of dealmaking by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies | A flurry of deals were inked by the likes of AstraZeneca, Johnson & Johnson, Roche and Boehringer Ingelheim with Asian companies. Big Pharma companies are also increasingly entrusting commercialization of some products in China to domestic firms.

Pharma 190
article thumbnail

StartUPDATES: New Developments from Healthcare Startups

MedCity News

Check out news from Kismet Health, the University of California at Berkeley’s life science startups, and the companies presenting at the Consumer Technology Association’s pitch contest at CES.

More Trending

article thumbnail

Positive data from schizophrenia clinical trials revealed

European Pharmaceutical Review

Utilising an add-on therapy for treatment-resistant schizophrenia (TRS) Newron Pharmaceuticals SPA has reported significant final, one-year results from its clinical trial 014/015, evaluating evenamide as an add-on therapy to antipsychotics in treatment-resistant schizophrenia (TRS). Evenamide According to Newron, evenamide is an orally available new chemical entity that normalises glutamate release induced by aberrant sodium channel activity (veratridine-stimulated).

article thumbnail

Eli Lilly Announces New Telehealth, Home Delivery Option for Popular Weight Loss Drug

Pharmaceutical Commerce

LillyDirect will facilitate access to medications by connecting patients with independent telehealth providers, bypassing the need to obtain a prescription from a physician and then going to a pharmacy to fill it.

article thumbnail

Urgent vs. Emergent: Alleviating Overcrowded Emergency Room Pressures

MedCity News

Crowded EDs will continue to plague the healthcare ecosystem and prevent the efficient delivery of care if the structure and education of care, resources, and availability are kept the same. UC can step in with its well-equipped and trained staff so that EDs can focus on what they do best, care for life-threatening situations.

Education 106
article thumbnail

AbbVie and Umoja to develop new CAR-T therapies for cancer

Pharmaceutical Technology

AbbVie and Umoja Biopharma partnered for the development of in-situ CAR-T cell therapy candidates for oncology targets.

Biopharma 122
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Lawmakers Must Protect California’s Kids and Fund Continuous Coverage Now

MedCity News

In predicting that the Medi-Cal coverage protections during the pandemic would end, advocates successfully pushed for California to adopt a continuous Medi-Cal coverage policy for children ages 0-5 – avoiding annual renewals during this vulnerable time in their childhood development. For this important protection to become a reality as soon as possible, we now need the Governor to fund and greenlight this policy immediately–in his January 2024 Budget proposal.

100
100
article thumbnail

In the post-pandemic era, three players still dominate the infectious disease market

PharmaVoice

Although three companies dominate the space, emerging infectious disease focus areas and a handful of other key players are augmenting the market.

Marketing 105
article thumbnail

Solera Health Expands Platform for Virtual Specialty Care

MedCity News

Solera Health has added virtual specialty care services to its Halo Platform. The new offering is in partnership with 9amHealth, Vori Health and Oshi Health.

104
104
article thumbnail

atai invests $50m in Beckley Psytech

pharmaphorum

Beckley Psytech has announced that is has received substantial strategic investment from atai Life Sciences, totalling $50 million, to accelerate the clinical development of short-duration psychedelics.

97
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

5 Healthcare Trends that Will Shape 2024

MedCity News

As we look into the future, 2024 promises a profound transformation. Here are five areas of focus for the upcoming year.

article thumbnail

Optimizing PPC for Multilocation Providers in Healthcare

Healthcare Success

Managing a PPC strategy for any sized business is complex and challenging. But organizations with dozens or hundreds of locations face even more hurdles: Multilocation providers must consider each location’s unique needs, competitive situation, and business objectives—compounding the complexity of managing an accurate and effective PPC (aka pay-per-click or paid search) strategy.

article thumbnail

Eli Lilly Launches Telehealth Platform to Sell Certain Drugs Directly to Consumers

PharmExec

The LillyDirect platform will allow patients who are prescribed the popular weight loss drug Zepbound to obtain the drug via Lilly’s at-home prescription delivery service.

article thumbnail

Owkin and Evotec partner to accelerate therapeutics in oncology and I&I

PharmaTimes

The companies will aim to select targets, discover and develop new therapeutics

95
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Welcome to Healthcare Unbound, powered by Clarify Health

Clarify Health

Welcome to our new podcast, Healthcare Unbound , where healthcare leaders and changemakers discuss ways to advance healthcare outcomes, costs, and affordability. Healthcare Unbound offers listeners a front-row seat to some of the brightest minds working to find solutions to the immense challenges we are facing in every corner of the industry. The podcast is the namesake of the Healthcare Unbound Summit we held in May 2022, where a select group of 150 industry thought leaders, innovators, and

article thumbnail

Immune cell helps predict skin cancer patients’ responses to immunotherapies

PharmaTimes

Vd1-gd T cells were effective in predicting positive responses to ICI therapy

article thumbnail

Merck Highlights Robust Oncology, Hematology Pipeline With Four Agents in Phase III Trials

Pharmaceutical Commerce

Trials will evaluate four novel agents for cancers that include essential thrombocythemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, non-small cell lung cancer, endometrial carcinoma, and metastatic castration-resistant prostate cancer.

52
article thumbnail

Novo Nordisk begins research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

PM360

Novo Nordisk, Omega Therapeutics, Inc. and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Setting the Stage for Specialty Drugs in 2024: Q&A with Tina Fresta, Strategic Solutions Senior Manager at epocrates

PharmExec

Tina Fresta, BA, MPH is the Strategic Solutions Senior Manager at epocrates, keeps a close eye on the pharmaceutical and bio science industry shifts, leveraging those insights to inform both our partners and our company of the most strategic approach to reach business goals.

article thumbnail

Intellia propels into 2024 with CRISPR pipeline updates

Pharmaceutical Technology

Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.

64
article thumbnail

Novartis Opens New Radioligand Therapy Manufacturing Facility in Indianapolis

Pharmaceutical Commerce

In the midst of being approved for commercial manufacturing of Pluvict, the 70,000 square-foot site was built specifically to accommodate RLT production.

article thumbnail

Signal: UK online pharmacies selling prescription drugs without proper checks

Pharmaceutical Technology

A BBC team was able to buy over 1600 prescription pills by supplying fake data, raising concerns over limited oversight.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Zelix Pharmaceuticals Files BLA for PET Imaging Agent for Renal Cell Carcinoma

PharmExec

Trial data show 89Zr-DFO-girentuximab was more effective than traditional PET/CT imaging in identifying malignant renal cell carcinoma lesions.

article thumbnail

DoD Grants Additional Funds to MediWound for Advancement of Non-Surgical Treatment for Field Care Burns

PharmaTech

MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.

52
article thumbnail

Pharmaceutical Technology Excellence Awards 2023: KAI Conversations

Pharmaceutical Technology

KAI, a technology company based in the UK, is a Category Award Winner for Innovation in the 2023 Pharmaceutical Technology Excellence Awards

article thumbnail

Pivotal Phase III Trials to Evaluate Four Promising Agents in Merck's Oncology, Hematology Pipeline

PharmExec

Merck is actively enrolling patients across Phase III trials for four novel candidates for hematologic malignancies and solid tumors.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A